4
Changes in Ownership
IONIS PHARMACEUTICALS INC Filed Acc 0000874015-26-000104
EVP, Chief Scientific Officer sold 85,089 shares at an average $82.93 ($7,056,216)
- EVP, Chief Scientific Officer acquired 65,089 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| BENNETT C FRANK EVP, Chief Scientific Officer | 2026-02-02 | Sale 10b5-1 | −20,000 | $82.60 | $1,651,980 | 80,293 | D: show line 1 in the form |
| BENNETT C FRANK EVP, Chief Scientific Officer | 2026-02-02 | Option exercise 10b5-1 | +48,626 | $60.89 | $2,960,837 | 128,919 | D: show line 2 in the form |
| BENNETT C FRANK EVP, Chief Scientific Officer | 2026-02-02 | Sale 10b5-1 | −48,626 | $83.03 | $4,037,339 | 80,293 | D: show line 3 in the form |
| BENNETT C FRANK EVP, Chief Scientific Officer | 2026-02-02 | Option exercise 10b5-1 | +16,463 | $32.60 | $536,694 | 96,756 | D: show line 4 in the form |
| BENNETT C FRANK EVP, Chief Scientific Officer | 2026-02-02 | Sale 10b5-1 | −16,463 | $83.03 | $1,366,897 | 80,293 | D: show line 5 in the form |
| Open-market sales · 85,089 sh · avg $82.93 · $7,056,216 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| BENNETT C FRANK EVP, Chief Scientific Officer | 2026-02-02 | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −16,463 | 2,406 | D: show line 6 in the form | |||||
| BENNETT C FRANK EVP, Chief Scientific Officer | 2026-02-02 | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −48,626 | 0 | D: show line 7 in the form |
Loading xslF345X05/edgardoc.xml…